What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?

Silvestris, Nicola

Silvestris, Nicola.

Silvestris N; Medical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, 70124 Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", 70124 Bari, Italy. Electronic address: n.silvestris@oncologico.bari.it.

EBioMedicine ; 74: 103733, 2021 Dec.

Article in English | MEDLINE | ID: covidwho-1610754

Subject(s)

BNT162 Vaccine/immunology; COVID-19/immunology; COVID-19/prevention & control; Immunity; Immunocompromised Host; SARS-CoV-2/immunology; Vaccines, Synthetic/immunology; mRNA Vaccines/immunology; BNT162 Vaccine/administration & dosage; Disease Susceptibility/immunology; Host-Pathogen Interactions/immunology; Humans; Vaccines, Synthetic/administration & dosage; mRNA Vaccines/administration & dosage

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Immunocompromised Host / SARS-CoV-2 / COVID-19 / MRNA Vaccines / BNT162 Vaccine / Immunity Topics: Vaccines Limits: Humans Language: English Journal: EBioMedicine Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google